Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Fludrocortisone for Sudden Hearing Loss

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified April 2015 by Oregon Health and Science University.
Recruitment status was:  Recruiting
Information provided by (Responsible Party):
Anh Nguyen-Huynh, Oregon Health and Science University Identifier:
First received: August 19, 2010
Last updated: April 21, 2015
Last verified: April 2015

August 19, 2010
April 21, 2015
August 2012
August 2016   (Final data collection date for primary outcome measure)
Hearing [ Time Frame: At one month ]
Hearing outcome will be determine by pure-tone and speech audiometry measured at the completion of a one-month course of treatment and compared with pre-treatment test results.
Same as current
Complete list of historical versions of study NCT01186185 on Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
Fludrocortisone for Sudden Hearing Loss
Mineralocorticoid Treatment for Sudden Sensorineural Hearing Loss
The standard of care treatment of sudden hearing loss uses a type of steroid called glucocorticoid. Examples of glucocorticoids are prednisone, methylprednisolone and dexamethasone. Not everybody recovers hearing with glucocorticoid treatment. Fludrocortisone is a different type of steroid called mineralocorticoid. Unlike glucocorticoids, which work by reducing inflammation, mineralocorticoids work by changing salt and fluid balance. In animal studies, fludrocortisone is at least as effective as glucocorticoid in preserving hearing. Fludrocortisone is not approved for the treatment of sudden hearing loss. The purpose of this study is to test whether fludrocortisone can treat sudden hearing loss.
Not Provided
Not Provided
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Hearing Loss, Sensorineural
Drug: Fludrocortisone
Fludrocortisone 0.2 mg by mouth daily for 30 days
Experimental: Fludrocortisone
Intervention: Drug: Fludrocortisone
Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
Unknown status
August 2016
August 2016   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Age 18 or older
  • Idiopathic sudden sensorineural hearing loss within 3 months
  • Failure to recover hearing with glucocorticoid treatment or inability to tolerate glucocorticoid

Exclusion Criteria:

  • Other diagnosis for the sudden hearing loss
  • Concurrent systemic use of another steroid
  • Hypersensitivity to fludrocortisone
  • Systemic fungal infection
  • Hypertension requiring two or more medications
  • Pitting edema
  • Cardiomegaly
  • Congestive heart failure
  • Electrolyte abnormality
  • Concurrent use of barbiturates, phenytoin, fosphenytoin, rifampin, or rifapentine
Sexes Eligible for Study: All
18 Years to 89 Years   (Adult, Senior)
Contact information is only displayed when the study is recruiting subjects
United States
Not Provided
Not Provided
Not Provided
Anh Nguyen-Huynh, Oregon Health and Science University
Oregon Health and Science University
Not Provided
Principal Investigator: Anh Nguyen-Huynh, MD PhD Oregon Health and Science University
Oregon Health and Science University
April 2015

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP